Drug Trial Radar · NCT07512583
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
178
Planned (sponsor's estimate)
Start
May 27, 2026
Primary completion
Mar 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, multi-cohort phase Ib/II clinical study to evaluate the efficacy and safety of TQB2930 in combination with TQB2102 in patients with HER2-expressing advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
TQB2930 injection+TQB2102 for injectionDrug
TQB2930 Injection is a Human Epidermal Growth Factor Receptor 2 (HER2) bispecific antibody. TQB2102 for injection is a HER2 - targeted dual epitope Antibody-Drug Conjugate (ADC).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 DoseTime frame: From first dose to 21days after first dose
- Overall response rate (ORR)Time frame: The estimated duration was 23 months from enrollment of the first patient to 6 months after enrollment of the last patient
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Tianjin Medical University Cancer Institute&Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.